Eftansomatropin alfa is intended for the treatment of children with growth hormone deficiency Credit: Africa Studio/Shutterstock.com.

Genexine has reported that the Phase III study of eftansomatropin alfa (GX-H9) for the treatment of children with growth hormone deficiency has met its primary endpoint of annualised height velocity (AHV) at week 52.

Being carried out by Genexine’s partner in China, the active-controlled, multi-centre, open-label, randomised study assessed the safety and efficacy of Genexine’s proprietary long-acting growth hormone, eftansomatropin alfa.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Patients received a weekly injection of eftansomatropin alfa and daily injections of Norditropin.

The mean AHV demonstrated for eftansomatropin alfa was 10.76 (cm/year) while it was 10.28 (cm/year) in Norditropin group with a difference of 0.47 [95% CI -0.06,1.00] and non-inferiority p-value <0.0001.

No drug discontinuation was reported due to adverse events related to the treatment and eftansomatropin alfa was observed to be well tolerated.

See Also:

Genexine president and CEO Neil Warma said: “This is a significant milestone for Genexine as we demonstrate our ability to bring our novel products to market and the value of our proprietary long-acting hyFc platform.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are excited to be preparing to submit the BLA in 2024 and advancing this product to market and to patients in China.

“We remain committed to our efforts to commercialise our leading products in various key markets.”

Handok is co-developing GX-H9 under a strategic alliance with Genexine.

Genexine is also engaged in developing GX-H9 for paediatric growth hormone deficiency, GX-E4 for CKD-induced anaemia, GX-188E for head and neck cancer and cervical cancer, and GX-I7 for multiple cancers.